Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Tong, Charles C L ^a   Ko, Eric C ^a   Sung, Max W ^a   Cesaretti, Jamie A ^b   Stock, Richard G ^a   Packer, Stuart H ^a   Forsythe, Kevin ^a   Genden, Eric M ^a   Schwartz, Myron ^a   Lau, K H Vincent ^a   Galsky, Matthew ^a   Ozao Choy, Junko ^a   Chen, Shu hsia ^a   Kao, Johnny ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Florida Radiation Oncology Group   (United States)

^c Good Samaritan Hospital Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTICLE; AUTOPSY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPERTENSION; IMAGE GUIDED RADIOTHERAPY; IMMUNE RESPONSE; KIDNEY CANCER; LIVER CANCER; LIVER FUNCTION TEST; LUNG CANCER; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OLIGOMETASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; PYRROLES; RADIOTHERAPY, IMAGE-GUIDED; SURVIVAL RATE;

EID: 84862997356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036979     Document Type: Article

References (33)

1. Hellman S, Weichselbaum RR, (1995) Oligometastases. J Clin Oncol 13: 8-10.
2. Macdermed DM, Weichselbaum RR, Salama JK, (2008) A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 98: 202-206.
3. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, et al. (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27: 1585-1591.
4. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, et al. (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112: 650-658.
5. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, et al. (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27: 1579-1584.
6. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, et al. (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27: 1572-1578.
7. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, et al. (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14: 5255-5259.
8. Milano MT, Constine LS, Okunieff P, (2008) Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 3: 36.
9. Marks LB, Prosnitz LR, (2000) Postoperative radiotherapy for lung cancer: the breast cancer story all over again? Int J Radiat Oncol Biol Phys 48: 625-627.
10. Seiwert TY, Salama JK, Vokes EE, (2007) The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4: 86-100.
11. Chow LQ, Eckhardt SG, (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884-896.
12. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, et al. (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63: 4009-4016.
13. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, et al. (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69: 2514-2522.
14. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, et al. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115: 3571-3580.
15. Wahl RL, Jacene H, Kasamon Y, Lodge MA, (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50: 122S-150S.
16. Je Y, Schutz FA, Choueiri TK, (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10: 967-974.
17. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
18. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
19. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
20. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
21. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
22. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
23. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
24. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
25. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
26. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
28. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, et al. (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25: 1677-1683.
29. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, et al. (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291.
30. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, et al. (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157.
31. Vu HL, Sikora AG, Fu S, Kao J, (2010) HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288: 149-155.
32. Lee Y, Auh SL, Wang Y, Burnette B, Meng Y, et al. (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114: 589-595.
33. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, et al. (2010) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol.